La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Aurora Spine Bilan de santé

Santé financière contrôle des critères 3/6

Aurora Spine possède un total de capitaux propres de $5.1M et une dette totale de $2.6M, ce qui porte son ratio d'endettement à 51.2%. Son actif total et son passif total sont $12.0M et de $7.0M.

Informations clés

53.5%

Ratio d'endettement

US$2.63m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$518.55k
Fonds propres	US$4.92m
Total du passif	US$7.07m
Total des actifs	US$11.99m

Mises à jour récentes de la santé financière

Recent updates

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

Aug 14

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ASG ( $8.6M ) dépassent ses passifs à court terme ( $3.6M ).

Passif à long terme: Les actifs à court terme de ASG ( $8.6M ) dépassent ses passifs à long terme ( $3.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de ASG ( 44% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de ASG a été réduit de 74.7% à 51.2% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ASG dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ASG dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 27.7 % chaque année

Aurora Spine Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Is Aurora Spine (CVE:ASG) A Risky Investment?

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Recent updates

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Aurora Spine Corporation(TSXV:ASG) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.44

New 90-day high: CA$0.38

Aurora Spine Plans A Major Multicenter Study of Its ZIPTM Interspinous Fixation Device for Relief of Back Pain

New 90-day high: CA$0.36

Third quarter 2020 earnings released: EPS US$0.01

Is Aurora Spine (CVE:ASG) A Risky Investment?